{"id":678,"date":"2026-04-12T18:14:12","date_gmt":"2026-04-12T18:14:12","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=678"},"modified":"2026-08-30T03:53:26","modified_gmt":"2026-08-30T03:53:26","slug":"lucileter-lettermovir-240-mgx30-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/ar\/product\/lucileter-lettermovir-240-mgx30-tablets\/","title":{"rendered":"LuciLeter"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/span><\/p>\n

These highlights do not include all the information needed to use LuciLeter safely and effectively. See full prescribing information for LuciLeter.<\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciLeter is a CMV DNA terminase complex inhibitor indicated for:<\/span><\/p>\n

\u2022 Prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). <\/span><\/p>\n

\u2022 Prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive\/Recipient CMV seronegative [D+\/R-]). <\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION <\/strong><\/strong><\/span><\/p>\n

\u2022 Adult and Pediatric Patients 12 Years of Age and Older and Weighing at least 30 kg Who Are HSCT Recipients or Adult and Pediatric Patients 12 Years of Age and Older and Weighing at least 40 kg Who Are Kidney Transplant Recipients:<\/strong><\/span><\/p>\n

o HSCT: 480 mg administered once daily orally or as an intravenous (IV) infusion over 1 hour through 100 days post-HSCT. In patients at risk for late CMV infection and disease, LuciLeter may be continued through 200 days post-HSCT. <\/span><\/p>\n

o Kidney Transplant: 480 mg administered once daily orally or as an IV infusion over 1 hour through 200 days post-transplant.<\/span><\/p>\n

\u2022 Pediatric Patients 6 Months to Less than 12 Years of Age or 12 Years of Age and Older and Weighing Less than 30 kg Who Are HSCT Recipients:<\/span><\/p>\n

    o HSCT: Dosing based on weight administered once daily orally or as an IV infusion over 1 hour through 100 days post-HSCT. In patients at risk for late CMV infection and disease, LuciLeter may be continued through 200 days post-HSCT. <\/span><\/p>\n

\u2022 Following the completion of LuciLeter prophylaxis, monitoring for CMV reactivation in HSCT recipients is recommended. <\/span><\/p>\n

\u2022 Dosage Adjustment: If LuciLeter is co-administered with cyclosporine, the dosage of LuciLeter should be decreased to 240 mg once daily in adult and pediatric patients 12 years of age and older.  If LuciLeter is co-administered with cyclosporine in pediatric patients less than 12 years of age, dose adjustment may be required.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Tablets: 240 mg\u00d730 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

LuciLeter is contraindicated with:<\/span><\/p>\n

 \u2022 Pimozide. <\/span><\/p>\n

 \u2022 Ergot Alkaloids. <\/span><\/p>\n

 \u2022 Pitavastatin and simvastatin when co-administered with cyclosporine.<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions: The concomitant use of LuciLeter with certain drugs may result in potentially significant drug interactions, some of which may lead to adverse reactions (LuciLeter or concomitant drugs) or reduced therapeutic effect of LuciLeter or the concomitant drug. Consult the full prescribing information for contraindications and dosage recommendations for concomitant drugs. <\/span><\/p>\n

\u2022 Risks Associated with Hydroxypropyl Betadex Excipient in Intravenous Formulation: Intravenous formulation of LuciLeter contains the excipient hydroxypropyl betadex. LuciLeter injection should be used only in patients unable to take oral therapy. If possible, intravenous administration should not exceed 4 weeks. In patients with renal impairment, accumulation of hydroxypropyl betadex may occur. Animal studies have shown the potential for hydroxypropyl betadex to cause ototoxicity. <\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Adult HSCT Patients: Most common adverse events (occurring in at least 10% of subjects in the LuciLeter group and at a frequency at least 2% greater than placebo) are nausea, diarrhea, vomiting, peripheral edema, cough, headache, fatigue, and abdominal pain.<\/span><\/p>\n

\u2022 Adult Kidney Transplant Patients: Most common adverse event (occurring in at least 10% of subjects in the LuciLeter group and at a frequency greater than valganciclovir) is diarrhea.<\/span><\/p>\n

\u2022 Pediatric Patients: Adverse events in pediatric patients are similar to adults. <\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Dosage Adjustment: If LuciLeter is co-administered with cyclosporine, the dosage of LuciLeter should be decreased to 240 mg once daily in adult and pediatric patients 12 years of age and older. (2.4) If LuciLeter is co-administered with cyclosporine in pediatric patients less than 12 years of age, dose adjustment may be required. <\/span><\/p>\n

\u2022 Co-administration of LuciLeter may alter the plasma concentrations of other drugs and other drugs may alter the plasma concentrations of LuciLeter. Consult the full prescribing information prior to and during treatment for potential drug interactions.<\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Renal Impairment: Closely monitor serum creatinine levels in patients with CLcr less than 50 mL\/min using LuciLeter injection.<\/span><\/p>\n

\u2022 Hepatic Impairment: LuciLeter is not recommended for patients with severe (Child-Pugh C) hepatic impairment.<\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciLeter is a CMV DNA terminase complex inhibitor indicated for: \u2022 Prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).<\/p>\n","protected":false},"featured_media":1995,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[48],"product_tag":[],"class_list":["post-678","product","type-product","status-publish","has-post-thumbnail","product_cat-other-medicines","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product\/678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/comments?post=678"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media\/1995"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media?parent=678"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_brand?post=678"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_cat?post=678"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_tag?post=678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}